Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

Monitoring of Osteonecrosis in Systemic Lupus Erythematosus Patients: A Systematic Review and Metaanalysis.

Hussein S, Suitner M, Béland-Bonenfant S, Baril-Dionne A, Vandermeer B, Santesso N, Keeling S, Pope JE, Fifi-Mah A, Bourré-Tessier J.

J Rheumatol. 2018 Jul 1. pii: jrheum.170837. doi: 10.3899/jrheum.170837. [Epub ahead of print]

2.

Randomized controlled trials of biologic treatment with methotrexate in RA may not reflect real world practice: A systematic review and assessment of pragmaticism.

Choi MY, Barnabe C, Barber CE, Bykerk V, Pope JE, Hazlewood GS.

Arthritis Care Res (Hoboken). 2018 Jun 15. doi: 10.1002/acr.23620. [Epub ahead of print]

PMID:
29908014
3.

Appropriate cardiovascular disease risk assessment in systemic lupus erythematosus may be lacking in rheumatology practice.

Esmaeilbeigi F, Pope JE.

Clin Exp Rheumatol. 2018 May 28. [Epub ahead of print]

PMID:
29846162
4.

Treatment algorithms for systemic sclerosis according to experts.

Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group.

Arthritis Rheumatol. 2018 May 21. doi: 10.1002/art.40560. [Epub ahead of print]

PMID:
29781586
5.

A systematic review of viral exposures as a risk for rheumatoid arthritis.

Kudaeva FM, Speechley MR, Pope JE.

Semin Arthritis Rheum. 2018 Mar 21. pii: S0049-0172(18)30095-7. doi: 10.1016/j.semarthrit.2018.03.011. [Epub ahead of print]

PMID:
29747994
6.

Safety of TNF inhibitors in pregnancy.

Pope JE.

Arthritis Rheumatol. 2018 May 7. doi: 10.1002/art.40540. [Epub ahead of print]

PMID:
29733552
7.

Repeat Testing of Antibodies and Complements in Systemic Lupus Erythematosus: When Is It Enough?

Raissi TC, Hewson C, Pope JE.

J Rheumatol. 2018 Jun;45(6):827-834. doi: 10.3899/jrheum.161365. Epub 2018 Apr 15.

PMID:
29657153
8.

Randomized Trials, Meta-Analyses, and Systematic Reviews: Using Examples from Rheumatology.

Pope JE, Hazlewood GS.

Rheum Dis Clin North Am. 2018 May;44(2):295-305. doi: 10.1016/j.rdc.2018.01.006. Review.

PMID:
29622296
9.

Mentoring women in medicine: a personal perspective.

Pope JE.

Lancet. 2018 Feb 10;391(10120):520-521. doi: 10.1016/S0140-6736(18)30243-5. No abstract available.

PMID:
29617225
10.

Physician global assessments for disease activity in rheumatoid arthritis are all over the map!

Turk M, Pope JE.

RMD Open. 2018 Feb 21;4(1):e000578. doi: 10.1136/rmdopen-2017-000578. eCollection 2018.

11.

High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years.

Barber CEH, Schieir O, Lacaille D, Marshall DA, Barnabe C, Hazlewood G, Thorne JC, Ahluwalia V, Bartlett SJ, Boire G, Haraoui B, Hitchon C, Keystone E, Tin D, Pope JE, Denning L, Bykerk VP; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):842-850. doi: 10.1002/acr.23439. Epub 2018 Mar 25.

12.

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis.

Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, Davies S, de Oliveira Pena J, Khanna D.

Rheumatology (Oxford). 2018 May 1;57(5):813-817. doi: 10.1093/rheumatology/kex504.

13.

Stress in patients diagnosed with rheumatoid arthritis compared to chronic pain.

Rice DB, Mehta S, Serrato J, Pope JE, Harth M, Sequeira K, Morley-Forster P, Shapiro AP, Teasell RW.

Rehabil Psychol. 2017 Nov;62(4):571-579. doi: 10.1037/rep0000103.

PMID:
29265872
14.

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.

Kivitz A, Olech E, Borofsky MA, Zazueta B, Navarro-Sarabia F, Radominski SC, Merrill JT, Pacheco-Tena C, Pei J, Nasmyth-Miller C, Pope JE.

J Rheumatol. 2018 Apr;45(4):456-464. doi: 10.3899/jrheum.161539. Epub 2017 Dec 15.

15.

Association of Opioid Usage with Spinal Cord Stimulation Outcomes.

Sharan AD, Riley J, Falowski S, Pope JE, Connolly AT, Karst E, Dalal N, Provenzano DA.

Pain Med. 2018 Apr 1;19(4):699-707. doi: 10.1093/pm/pnx262.

PMID:
29244102
16.

Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.

Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, Hitchon C, Jamal S, Thorne JC, Tin D, Keystone EC, Haraoui B, Goodman SM, Bykerk VP; CATCH Investigators.

Arthritis Care Res (Hoboken). 2017 Nov 30. doi: 10.1002/acr.23457. [Epub ahead of print]

PMID:
29193840
17.

Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).

Pope JE, Rampakakis E, Movahedi M, Cesta A, Li X, Couto S, Sampalis JS, Bombardier C; and the Ontario Best Practices Research Initiative investigators.

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):215-222. Epub 2017 Oct 23.

18.

Editorial: Bench to Bedside-and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe.

Pope JE, Lee JJ, Denton CP.

Arthritis Rheumatol. 2018 Feb;70(2):155-156. doi: 10.1002/art.40373. Epub 2017 Dec 29. No abstract available.

PMID:
29121455
19.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

PMID:
29077900
20.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

21.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2018 Jan;77(1):128-132. doi: 10.1136/annrheumdis-2017-211480. Epub 2017 Oct 23.

PMID:
29061853
22.

Through the Looking Glass: Specialty Influence on SCS Outcomes.

Boortz-Marx R, Qadri MYJ, Roy L, Pope JE, Deer TR, Runyon SL.

Neuromodulation. 2017 Oct;20(7):740-741. doi: 10.1111/ner.12694. No abstract available.

PMID:
29024484
23.

Trial methodology in scleroderma: Avoiding a shot in the dark.

Pope JE.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v1-v3. doi: 10.1093/rheumatology/kex204. No abstract available.

PMID:
28992175
24.

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, Matucci-Cerinic M, Denton CP, Medsger TA Jr, Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Müller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE.

Scand J Rheumatol. 2018 Jan;47(1):62-70. doi: 10.1080/03009742.2017.1299793. Epub 2017 Oct 9.

PMID:
28990485
25.

Multicenter Retrospective Study of Neurostimulation With Exit of Therapy by Explant.

Pope JE, Deer TR, Falowski S, Provenzano D, Hanes M, Hayek SM, Amrani J, Carlson J, Skaribas I, Parchuri K, McRoberts WP, Bolash R, Haider N, Hamza M, Amirdelfan K, Graham S, Hunter C, Lee E, Li S, Yang M, Campos L, Costandi S, Levy R, Mekhail N.

Neuromodulation. 2017 Aug;20(6):543-552. doi: 10.1111/ner.12634. Epub 2017 Jul 17.

PMID:
28714533
26.

Novel treatment strategies in rheumatoid arthritis.

Burmester GR, Pope JE.

Lancet. 2017 Jun 10;389(10086):2338-2348. doi: 10.1016/S0140-6736(17)31491-5. Review.

PMID:
28612748
27.

Editorial: The Effect of Ethnicity on Cardiovascular Outcomes in Systemic Lupus Erythematosus Is Perhaps Not a Paradox.

Pope JE, Weisman MH, Sjöwall C.

Arthritis Rheumatol. 2017 Sep;69(9):1707-1709. doi: 10.1002/art.40173. No abstract available.

PMID:
28598003
28.

Pulmonary arterial hypertension in scleroderma: care gaps in screening.

Pope JE.

Arthritis Res Ther. 2017 Jun 6;19(1):128. doi: 10.1186/s13075-017-1347-4.

29.

Reinstituting the Bolus - New Reasoning for an Existing Technique.

McRoberts PW, Pope JE, Apostol C.

Pain Physician. 2017 May;20(4):E601-E603.

30.

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP.

J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.

31.

Evaluation of Abbott's BurstDR stimulation device for the treatment of chronic pain.

Deer TR, Campos LW, Pope JE.

Expert Rev Med Devices. 2017 Jun;14(6):417-422. doi: 10.1080/17434440.2017.1330147. Review.

PMID:
28498725
32.

Effect of post-hospital discharge telephonic intervention on hospital readmissions in a privately insured population in Australia.

Hamar GB, Coberley C, Pope JE, Cottrill A, Verrall S, Larkin S, Rula EY.

Aust Health Rev. 2018 Jun;42(3):241-247. doi: 10.1071/AH16059.

PMID:
28390471
33.

Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.

Zhang T, Pope JE.

Rheumatology (Oxford). 2017 Jul 1;56(7):1144-1153. doi: 10.1093/rheumatology/kex065. Review.

PMID:
28379501
34.

Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.

Nevskaya T, Baron M, Pope JE; Canadian Scleroderma Research Group.

Rheumatology (Oxford). 2017 Jul 1;56(7):1111-1122. doi: 10.1093/rheumatology/kex015.

PMID:
28340090
35.

Editorial: "Weighing in" on the Framingham Osteoarthritis Study: Measuring Biomechanical and Metabolic Contributions to Osteoarthritis.

Appleton CT, Hawker GA, Hill CL, Pope JE.

Arthritis Rheumatol. 2017 Jun;69(6):1127-1130. doi: 10.1002/art.40089. Epub 2017 May 10. No abstract available.

36.

A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors.

Nevskaya T, Gamble MP, Pope JE.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):700-710. Epub 2017 Feb 24. Review.

PMID:
28240590
37.

The well-being valuation model: a method for monetizing the nonmarket good of individual well-being.

Sidney JA, Jones A, Coberley C, Pope JE, Wells A.

Health Serv Outcomes Res Methodol. 2017;17(1):84-100. doi: 10.1007/s10742-016-0161-9. Epub 2016 Oct 25.

38.

Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines.

Pellar RE, Pope JE.

Semin Arthritis Rheum. 2017 Jun;46(6):767-774. doi: 10.1016/j.semarthrit.2016.12.003. Epub 2016 Dec 9. Review.

PMID:
28088339
39.

The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.

Barra LJ, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, Thorne CJ, Tin D, Keystone EC, Haraoui B, Jamal S, Bykerk VP; CATCH group.

Rheumatology (Oxford). 2017 May 1;56(5):768-776. doi: 10.1093/rheumatology/kew474.

PMID:
28073956
40.

Connective tissue disease: Reflections on the EULAR recommendations for the treatment of systemic sclerosis.

Pope JE.

Nat Rev Rheumatol. 2017 Mar;13(3):134-136. doi: 10.1038/nrrheum.2016.212. Epub 2017 Jan 5. No abstract available.

PMID:
28053333
41.

The Neurostimulation Appropriateness Consensus Committee (NACC) Safety Guidelines for the Reduction of Severe Neurological Injury.

Deer TR, Lamer TJ, Pope JE, Falowski SM, Provenzano DA, Slavin K, Golovac S, Arle J, Rosenow JM, Williams K, McRoberts P, Narouze S, Eldabe S, Lad SP, De Andrés JA, Buchser E, Rigoard P, Levy RM, Simpson B, Mekhail N.

Neuromodulation. 2017 Jan;20(1):15-30. doi: 10.1111/ner.12564. Epub 2017 Jan 2.

PMID:
28042918
42.

The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks.

Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M, Wallace MS, Grider JS, Levy RM, Prager J, Rosen SM, Saulino M, Yaksh TL, De Andrés JA, Abejon Gonzalez D, Vesper J, Schu S, Simpson B, Mekhail N.

Neuromodulation. 2017 Feb;20(2):155-176. doi: 10.1111/ner.12579. Epub 2017 Jan 2. Review.

PMID:
28042914
43.

The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for Infection Prevention and Management.

Deer TR, Provenzano DA, Hanes M, Pope JE, Thomson SJ, Russo MA, McJunkin T, Saulino M, Raso LJ, Lad SP, Narouze S, Falowski SM, Levy RM, Baranidharan G, Golovac S, Demesmin D, Witt WO, Simpson B, Krames E, Mekhail N.

Neuromodulation. 2017 Jan;20(1):31-50. doi: 10.1111/ner.12565. Epub 2017 Jan 2. Erratum in: Neuromodulation. 2017 Jul;20(5):516.

PMID:
28042909
44.

The Polyanalgesic Consensus Conference (PACC): Recommendations for Trialing of Intrathecal Drug Delivery Infusion Therapy.

Deer TR, Hayek SM, Pope JE, Lamer TJ, Hamza M, Grider JS, Rosen SM, Narouze S, Perruchoud C, Thomson S, Russo M, Grigsby E, Doleys DM, Jacobs MS, Saulino M, Christo P, Kim P, Huntoon EM, Krames E, Mekhail N.

Neuromodulation. 2017 Feb;20(2):133-154. doi: 10.1111/ner.12543. Epub 2017 Jan 2. Review.

PMID:
28042906
45.

The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices.

Deer TR, Narouze S, Provenzano DA, Pope JE, Falowski SM, Russo MA, Benzon H, Slavin K, Pilitsis JG, Alo K, Carlson JD, McRoberts P, Lad SP, Arle J, Levy RM, Simpson B, Mekhail N.

Neuromodulation. 2017 Jan;20(1):51-62. doi: 10.1111/ner.12542. Epub 2017 Jan 2. Erratum in: Neuromodulation. 2017 Jun;20(4):407.

PMID:
28042905
46.

The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines.

Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, De Andrés JA, Erdek M, Patin D, Grider JS, Doleys DM, Jacobs MS, Yaksh TL, Poree L, Wallace MS, Prager J, Rauck R, DeLeon O, Diwan S, Falowski SM, Gazelka HM, Kim P, Leong M, Levy RM, McDowell G II, McRoberts P, Naidu R, Narouze S, Perruchoud C, Rosen SM, Rosenberg WS, Saulino M, Staats P, Stearns LJ, Willis D, Krames E, Huntoon M, Mekhail N.

Neuromodulation. 2017 Feb;20(2):96-132. doi: 10.1111/ner.12538. Epub 2017 Jan 2. Review. Erratum in: Neuromodulation. 2017 Jun;20(4):405-406.

PMID:
28042904
47.

Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues.

Richard N, Hudson M, Gyger G, Baron M, Sutton E, Khalidi N, Pope JE, Carrier N, Larché M, Albert A, Fortin PR, Thorne C, Masetto A; on the behalf of Canadian Scleroderma Research Group.

Rheumatology (Oxford). 2017 Apr 1;56(4):581-588. doi: 10.1093/rheumatology/kew441.

PMID:
28013205
48.
49.

Emerging drugs and therapeutics for systemic sclerosis.

Lee JJ, Pope JE.

Expert Opin Emerg Drugs. 2016 Dec;21(4):421-430. Epub 2016 Nov 18. Review.

PMID:
27813423
50.

The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study.

O'Connor A, Thorne C, Kang H, Tin D, Pope JE.

BMC Musculoskelet Disord. 2016 Aug 24;17(1):364. doi: 10.1186/s12891-016-1213-6.

Supplemental Content

Support Center